Management Quality -- 8.5/10
CEO Brian Tyler has led McKesson since April 2019 (~7 years), navigating opioid litigation
settlements, the European exit, and a GLP-1-fueled acceleration to record results. Management
has raised EPS guidance every quarter for three consecutive fiscal years, delivered an 18%
five-year adjusted EPS CAGR, and driven ROIC above 30%. CFO Britt Vitalone (since 2018)
brings exceptional credibility with the Street. This is a textbook under-promise,
over-deliver culture.
Weight: 20%
CEO Tenure
~7 Years
Brian Tyler, CEO since April 2019
5-Year Adj. EPS CAGR
18%
Consistent double-digit compounding
ROIC
>30%
+1,900bps since FY2020
Guidance Raises
Every Q, 3 Years
Raised EPS guide every quarter since FY2024
EPS Guidance Accuracy
| Fiscal Year | Initial EPS Guide | Final EPS Guide | Actual Adj. EPS | Verdict |
|---|---|---|---|---|
| FY2024 | $26.10-$26.90 | $27.25-$27.65 | ~$27.42 (implied) | Raised 3x, delivered |
| FY2025 | $31.25-$32.05 | $32.55-$32.95 | ~$33.10 (implied) | Raised 3x, beat |
| FY2026 | $36.75-$37.55 | $38.80-$39.20 | In progress | Raised 3x through Q3 |
FY2026 midpoint raised from $37.15 to $39.00 (+$1.85, +5%) through 3 quarters.
Daloopa IDs linked above for each guidance data point.
Source: Daloopa, earnings call transcripts.
FCF Guidance Accuracy
| Fiscal Year | Initial FCF Guide | Final FCF Guide | Actual FCF | Verdict |
|---|---|---|---|---|
| FY2024 | $3.7-4.1B | $3.2-3.6B (lowered Q3) | $3.6B | Met low end |
| FY2025 | $4.8-5.2B | $4.8-5.2B (held) | $5.2B | Beat at high end |
| FY2026 | $4.4B-$4.8B | $4.4-4.8B | In progress | -- |
Source: Daloopa, earnings call transcripts.
Promise Tracking
| Promise | Result | Status |
|---|---|---|
| Oncology platform expansion | FL Cancer Specialists acquired, Prism Vision added, segment growing 37% YoY | DELIVERED |
| European exit | Norway divestiture completed Jan 2026 -- final step of multi-year plan | DELIVERED |
| Med-Surg IPO by H2 CY2027 | TSAs in place as of Jan 1, 2026; on track for H2 CY2027 | ON TRACK |
| AI/automation efficiency gains | 120 more patients/FTE, 75% DSCSA inquiry deflection, 138bp opex leverage | DELIVERING |
| ROIC improvement | ROIC increased >1,900bps since FY2020, now exceeding 30% | DELIVERED |
Source: Earnings call transcripts FY2024-FY2026, company press releases.
Capital Allocation
| Quarter | CY23Q2 | CY24Q1 | CY24Q4 | CY25Q2 | CY25Q4 |
|---|---|---|---|---|---|
| Diluted Shares (M) | 136.6 | 131.6 | 126.6 | 125.5 | 123.7 |
4-year cumulative TSR: $514.93 vs $179.18 for the S&P 500 Healthcare Index (per management
proxy). 5-year adjusted operating profit CAGR of 11%. Capital allocation is disciplined and
shareholder-aligned.
Minor Deduction
Opioid litigation tail risk (-0.5 pt). The $26B industry settlement is largely
resolved, but FY2025 still included a $108M claims/litigation charge. Headline risk persists
and Rite Aid bankruptcy recovery ($160M credit in Q3) shows ongoing exposure to customer credit
risk. This is a legacy issue -- not reflective of current management -- but it remains a minor
overhang on the management narrative.
Score Rationale
8.5/10. Brian Tyler (CEO since 2019) and Britt Vitalone (CFO since 2018) form
one of the most credible leadership duos in healthcare distribution. The guidance track record
is exceptional: EPS guidance raised every quarter for three consecutive fiscal years, with
FY2025 actual beating the high end. Promise delivery is strong across all five tracked
initiatives -- oncology expansion, European exit, Med-Surg separation, AI/automation, and ROIC
improvement. Capital allocation is disciplined with ~$2B/year buybacks driving 3-4% annual
share count reduction. The minor deduction reflects the opioid litigation tail risk, which is
largely resolved via the $26B settlement but still generates periodic headline noise and
litigation charges. Not a 9 because the opioid legacy stain and the Med-Surg IPO execution
risk remain open items.
Data sourced from Daloopa, earnings call transcripts, and company disclosures.